Myelodysplastic/myeloproliferative disease
MONDO:0020077Clonal myeloid disorders that possess both dysplastic and proliferative features but are not properly classified as either MYELODYSPLASTIC SYNDROMES or MYELOPROLIFERATIVE disorderS.
1771 clinical trials for this condition and its sub-types, 31 tagged with Myelodysplastic/myeloproliferative disease itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Myelodysplastic/myeloproliferative disease
-
Chronic myelomonocytic leukemia 166 trials · 186 incl. sub-types
1 sub-type
- Juvenile myelomonocytic leukemia 24 trials
-
Could detoxing metals boost chemo for leukemia?
Disease control Recruiting nowThis early-stage trial is testing whether two drugs that lower metal levels in the body can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) respond better to chemotherapy. The study will enroll 58 adults and aims to find the safest dose and check f…
Phase 1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Sep 20, 2026 00:00 UTC
-
New combo aims to boost transplant success in rare blood cancer
Disease control Recruiting nowThis study tests whether giving a chemotherapy drug (decitabine) plus a targeted therapy (ruxolitinib, fedratinib, or pacritinib) before a stem cell transplant helps people with advanced myeloproliferative neoplasms (MPN) get to transplant and have better outcomes. About 25 adult…
Phase 2 • Sponsor: University of Washington • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
New targeted drug shows promise for Hard-to-Treat blood cancers
Disease control Recruiting nowThis study is testing a new drug called BGB-11417 (sonrotoclax) in people with acute myeloid leukemia (AML), myelodysplastic syndromes (MDS), or related blood cancers. The drug works by blocking a protein that helps cancer cells survive. The trial will give the drug alone or toge…
Phase 1/2 • Sponsor: BeOne Medicines • Aim: Disease control
Last updated Sep 16, 2026 00:00 UTC
-
New combo therapy for rare blood cancers put on hold
Disease control Recruiting nowThis phase 2 trial compares a drug combo (ASTX727 plus iadademstat) against ASTX727 alone for people with advanced myeloproliferative neoplasms (MPNs), a group of rare blood cancers. The study aims to see if adding iadademstat improves complete response rates. However, the trial …
Phase 2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New drug combo aims to shrink Hard-to-Treat blood cancers
Disease control Recruiting nowThis study tests a new antibody called axatilimab, given with or without the chemotherapy drug azacitidine, for people with advanced myeloproliferative neoplasms (MPN), MPN/MDS overlap, or high-risk chronic myelomonocytic leukemia (CMML). The goal is to find the safest dose and s…
Phase 1/2 • Sponsor: Uma Borate • Aim: Disease control
Last updated Aug 29, 2026 00:00 UTC
-
New combo aims to tame Graft-Versus-Host disease in older blood cancer patients
Disease control Recruiting nowThis phase 2 trial tests whether adding the drug ruxolitinib to standard care can prevent graft-versus-host disease (GVHD) in older patients with myelofibrosis or MDS/MPN overlap syndromes who receive a donor stem cell transplant. About 50 participants will get ruxolitinib before…
Phase 2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Immune booster: personalized NK cells aim to wipe out blood cancer after transplant
Disease control Recruiting nowThis phase 2 trial tests whether giving patients their own personalized natural killer (NK) cells after chemotherapy and a cord blood transplant can help kill any remaining cancer cells. The study includes 100 people with various blood cancers like leukemia, lymphoma, and multipl…
Phase 2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
New pill targets hard-to-treat blood cancers in early trial
Disease control Recruiting nowThis early-stage study tests a new oral drug called onvansertib for people with chronic myelomonocytic leukemia (CMML) or related blood cancers that have returned or stopped responding to standard treatments. The drug works by blocking a protein that helps cancer cells grow. The …
Phase 1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Can pressurized oxygen boost stem cell transplants?
Disease control Recruiting nowThis early-phase study tests whether adding hyperbaric oxygen therapy (breathing pure oxygen in a pressurized chamber) to standard stem cell transplant preparation is safe and helps recovery. It involves 24 adults with various blood cancers, such as leukemia and myelofibrosis. Th…
Early phase 1 • Sponsor: Omar Aljitawi • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune cells armed to hunt down hidden leukemia
Disease control Recruiting nowThis early-phase trial tests a new cell therapy for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who still have small amounts of cancer cells after standard treatment. The therapy uses the patient's own blood cells, armed with a special antibody to t…
Phase 1 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New hope for tough blood cancers: LP-118 trial launches
Disease control Recruiting nowThis early-stage study tests a new oral drug, LP-118, in up to 100 adults with blood cancers like lymphoma, leukemia, or myeloma that returned or didn't respond to prior therapy. The main goals are to find the safest dose and see if the drug can shrink tumors or slow the disease.…
Phase 1 • Sponsor: Newave Pharmaceutical Inc • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New Triple-Drug cocktail targets tough leukemia mutations
Disease control Recruiting nowThis study is for people with certain blood cancers (like acute myeloid leukemia) that have a specific genetic change called a FLT3 mutation. The cancers have either come back or not responded to prior treatment. The trial tests a combination of three drugs—azacitidine, venetocla…
Phase 1/2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Blood cancer bleeding breakthrough? TXA trial aims to cut hospitalizations
Symptom relief Recruiting nowThis study tests whether tranexamic acid (TXA), a drug that prevents blood clots from breaking down, can safely reduce bleeding in people with myelodysplastic syndromes (MDS) or acute myeloid leukemia (AML). About 75 outpatients receiving less-intensive chemotherapy will be rando…
Phase 2 • Sponsor: University of Manitoba • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Telehealth program aims to improve end-of-life conversations for older cancer patients
Knowledge-focused Recruiting nowThis study tests a telehealth program that helps older adults (60+) with blood cancers like leukemia or MDS talk to their doctors about their care wishes. The program also helps them fill out advance directive forms. Researchers want to see if it improves communication and reduce…
Sponsor: University of Rochester • Aim: Knowledge-focused
Last updated Sep 13, 2026 00:00 UTC
-
A nationwide effort to map a rare blood Cancer's toll
Knowledge-focused Recruiting nowResearchers in Italy are building a large registry of adults newly diagnosed with myelodysplastic syndromes, a group of blood cancers where the bone marrow does not make enough healthy blood cells. The study will collect data on up to 10,000 people to measure how many new cases o…
Sponsor: Fondazione Italiana Sindromi Mielodisplastiche-ETS • Aim: Knowledge-focused
Last updated Sep 06, 2026 00:00 UTC
-
New registry aims to unlock secrets of cancer in older adults
Knowledge-focused Recruiting nowThis research study creates a registry of older adults with cancer to collect information about their health, treatments, and outcomes. Participants complete a geriatric assessment and allow researchers to follow their medical records. The goal is to better understand how cancer …
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Blood cancer Patients' samples fuel future research
Knowledge-focused Recruiting nowThis study collects blood, tissue, and body fluid samples from up to 15,000 people with blood cancers or related disorders. The samples are stored in a central lab for future research on diagnosis, prognosis, and immune monitoring. Participants do not receive any treatment as par…
Sponsor: UNC Lineberger Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:55 UTC